Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Orexigen Therapeutics (Nasdaq: OREX ) has received the dreaded one-star ranking.
With that in mind, let's take a closer look at Orexigen's business and see what CAPS investors are saying about the stock right now.
Orexigen facts
| Headquarters (founded) | La Jolla, Calif. (since 2002) |
| Market Cap | $399.9 million |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $3.4 million |
| Management | CEO Michael Narachi (since 2009) Acting CFO Joseph Hagan (since 2011) |
| Return on Capital (average, past 3 years) | (51.4%) |
| Cash/Debt | $138.6 million / $0 |
| Competitors | Abbott Labs Arena Pharmaceuticals (Nasdaq: ARNA ) GlaxoSmithKline |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 24% of the 262 All-Star members who have rated Orexigen believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those bears, jed71, cautioned Fools about getting too excited over Orexigen's recent speculation-fueled surge:
Obesity drug still not approved yet. Run up based on expectations and approval received by a different company, Arena Pharma, for a similar obesity drug. It will not hold the run up, because, well, [Orexigen] never holds these run ups.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've compiled a special free report for investors called "Discover the Next Rule-Breaking Multibagger," which uncovers another small-cap growth play with big potential. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Report this Comment On June 29, 2012, at 12:44 PM, mincasa wrote:
Monkey see ,Monkey do attitude with traders who lack any common sense or real market experience. The only one's benefeting from this run up are the WS theives and they will be pulling the rug from all these ARNA investors who made money and about to loose it all to OREX and VVUS.. be careful, and do your DD before thinking that you are (day traders) are the king of the hill. Big thugs on WS are bating the week hands..OREX and VVUS are the riskiest stocks at the moment. ARNA is in a much lower risk, ad they are in a different stage and playing in a different field..pls.do not get exicted and let greed blind you, you will loose ..good luck and god bless you all,
Add your comment.